白云山(00874)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00874 白云山

开市前 11-27 09:19:14

17.980

+0.000

0.00%

最高17.980	最低17.980	成交量0.00
今开17.980	昨收17.980	日振幅0.00%
总市值292.32亿	流通市值39.56亿	总股本16.26亿
成交额0.00	换手率0.00%	流通股本2.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00874","market":"HK","secType":"STK","nameCN":"白云山","latestPrice":17.98,"timestamp":1732669200097,"preClose":17.98,"halted":0,"volume":0,"delay":0,"floatShares":220000000,"shares":1625790949,"eps":2.6748428,"marketStatus":"开市前","marketStatusCode":1,"change":0,"latestTime":"11-27 09:19:14","open":17.98,"high":17.98,"low":17.98,"amount":0,"amplitude":0,"askPrice":18,"askSize":10000,"bidPrice":17.98,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":2.257762311070648,"exchange":"SEHK","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732671000000},"adr":0,"listingDate":878140800000,"adjPreClose":17.98,"dividendRate":0.068506,"openAndCloseTimeList":[[1732671000000,1732680000000],[1732683600000,1732694400000]],"volumeRatio":0,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600332","market":"SH","secType":"STK","nameCN":"白云山","latestPrice":28.38,"timestamp":1732670352000,"preClose":28.18,"halted":0,"volume":0,"delay":0,"premium":"-40.91"}},"requestUrl":"/m/hq/s/00874","defaultTab":"news","newsList":[{"id":"2486007295","title":"广药集团迎新董事长 白云山尚未确定“一把手”","url":"https://stock-news.laohu8.com/highlight/detail?id=2486007295","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486007295?lang=zh_cn&edition=full","pubTime":"2024-11-26 23:18","pubTimestamp":1732634326,"startTime":"0","endTime":"0","summary":"11月26日，《每日经济新闻》记者获悉，广州公交集团原党委书记、董事长李小军，已履新广药集团董事长。这意味着广药集团前董事长李楚源接受调查以后，空悬了4个月的董事长一职终于确定。李小军1971年12月出生，长期在纪委系统工作，曾任广州市黄埔区纪委副书记、广百集团纪委书记、广州公交集团党委副书记，副董事长，总经理。2023年2月，广州市政府任命李小军为广州公交集团董事长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411263251364760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411263251364760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1606","00874","BK1521","BK1191","BK1197","BK1515"],"gpt_icon":0},{"id":"2486008031","title":"一心堂预计2025年向白云山关联采购总额不超7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486008031","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486008031?lang=zh_cn&edition=full","pubTime":"2024-11-26 21:11","pubTimestamp":1732626713,"startTime":"0","endTime":"0","summary":"公司预计向关联方白云山采购中西成药合计不超过7亿元，销售中药材、中西成药及提供广告服务、咨询服务、促销服务合计不超过5000万元。2024年度截至披露日，公司与白云山的实际交易金额为1487万元，远低于预计的1.5亿元，差异为90.09%；采购方面，实际发生金额为3.2亿元，也低于预计的6.8亿元，差异为52.97%。文章来源：财中社一心堂预计2025年向白云山关联采购总额不超7亿元","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126213926abe0a343&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126213926abe0a343&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","00874","BK1606","BK1521","BK1197"],"gpt_icon":0},{"id":"2486083341","title":"白云山：控股子公司头孢地尼颗粒获得《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2486083341","media":"证券日报","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486083341?lang=zh_cn&edition=full","pubTime":"2024-11-25 20:07","pubTimestamp":1732536468,"startTime":"0","endTime":"0","summary":"证券日报网讯11月25日晚间，白云山发布公告称，近日，公司控股子公司广州白云山天心制药股份有限公司收到国家药品监督管理局核准签发关于头孢地尼颗粒（50mg）的《药品注册证书》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411253249979430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1521","BK1191","BK1197","00874","BK1606"],"gpt_icon":0},{"id":"2486700193","title":"挪威中央银行减持白云山(00874)29.2万股 每股作价约18.13港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486700193","media":"智通财经网","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486700193?lang=zh_cn&edition=full","pubTime":"2024-11-25 19:08","pubTimestamp":1732532880,"startTime":"0","endTime":"0","summary":"联交所最新资料显示，11月20日，挪威中央银行减持白云山(00874)29.2万股，每股作价18.1349港元，总金额约为529.54万港元。减持后最新持股数目为1303.1万股，最新持股比例为5.93%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-25/doc-incxhuth8076493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK0196","BK1521","BK0096","BK0028","BK1191","BK1606","BK0175","BK1197","600332","BK0239","BK0097","00874","BK0012","BK0183","BK0070","BK0188"],"gpt_icon":0},{"id":"2486701357","title":"白云山子公司收药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486701357","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486701357?lang=zh_cn&edition=full","pubTime":"2024-11-25 18:08","pubTimestamp":1732529318,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）11月25日晚间，白云山（600332）发布公告称，公司控股子公司广州白云山天心制药股份有限公司（以下简称“天心制药”）收到国家药品监督管理局核准签发关于头孢地尼颗粒（50mg）的《药品注册证书》。白云山表示，本次获得头孢地尼颗粒（50mg）《药品注册证书》，丰富了天心制药口服抗生素产品的种类，有利于提升公司市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411253249898553.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411253249898553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1191","BK1197","BK1521","BK1606","00874"],"gpt_icon":0},{"id":"2486705548","title":"白云山(00874.HK)子公司获药监局签发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705548","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486705548?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:33","pubTimestamp":1732527180,"startTime":"0","endTime":"0","summary":"白云山(00874.HK) 公布，子公司天心制药收到国家药监局核准签发关于头孢地尼颗粒的药品注册证书。该药属第三代头孢类抗生素，主要是通过抑制细菌细胞壁的合成而起到杀菌作用，是一种广谱的抗菌素，于2002年在中国获批上市。公司指，天心制药在此药物研发项目上已投入研发费用合计约606万元人民币。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-25 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200309160210932_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200309160210932_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1399298/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK0188","BK1197","BK0070","BK1521","00874","600332","BK0028","BK0175","BK1606","BK1515","BK0012","BK0096","BK0097","BK0196","BK0183","BK0239"],"gpt_icon":0},{"id":"2486469703","title":"白云山(00874)子公司天心制药收到关于头孢地尼颗粒(50mg)的《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2486469703","media":"智通财经网","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486469703?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:32","pubTimestamp":1732527173,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山 发布公告，近日，该公司控股子公司广州白云山天心制药股份有限公司收到国家药品监督管理局核准签发关于头孢地尼颗粒的《药品注册证书》。2022年7月，天心制药向国家药品监督管理局递交药品注册申请获受理。截至目前，天心制药在头孢地尼颗粒研发项目上已投入研发费用合计约人民币606万元(未审计)。本次获得头孢地尼颗粒《药品注册证书》，丰富了天心制药口服抗生素产品的种类，有利于提升本公司市场竞争力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0070","BK0175","BK0183","BK0196","BK1606","00874","01477","BK0097","600332","BK1515","BK0096","BK0028","BK1197","BK0012","BK1574","BK1191","BK0188","BK0239","BK1521"],"gpt_icon":0},{"id":"2486035807","title":"白云山最新公告：子公司天心制药收到头孢地尼颗粒（50mg）药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486035807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486035807?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:21","pubTimestamp":1732526464,"startTime":"0","endTime":"0","summary":"白云山公告，控股子公司天心制药近日收到国家药品监督管理局核准签发关于头孢地尼颗粒（50mg）的《药品注册证书》。头孢地尼颗粒属第三代头孢类抗生素，是一种广谱抗菌素，适用于治疗多种细菌感染，同时适用于成人与儿童。天心制药在该项目上已投入研发费用约606万元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500023458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","BK0028","BK0097","BK0070","BK0183","BK0196","00874","BK1197","BK1515","BK1521","BK1606","600332","BK1574","BK0175","01477","BK0239","BK0096","BK1191"],"gpt_icon":0},{"id":"2486703109","title":"白云山子公司获头孢地尼颗粒药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486703109","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486703109?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:17","pubTimestamp":1732526247,"startTime":"0","endTime":"0","summary":"财中社11月25日电白云山（600332/00874）发布关于子公司收到药品注册证书的公告。控股子公司天心制药近日收到国家药品监督管理局核准签发的头孢地尼颗粒（50mg）的《药品注册证书》。该药品为化学药品4类，注册证书编号为2024S02726，有效期至2029年11月14日。头孢地尼颗粒是一种广谱抗生素，适用于治疗多种细菌感染。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411253249866540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00874","BK1521","BK1191","BK1197","BK1515","BK1606"],"gpt_icon":0},{"id":"2486708909","title":"白云山(600332.SH)子公司收到头孢地尼颗粒药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486708909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486708909?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:14","pubTimestamp":1732526060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(600332.SH)发布公告，公司控股子公司广州白云山天心制药股份有限公司(简称“天心制药”)收到国家药品监督管理局核准签发关于头孢地尼颗粒(50mg)的《药品注册证书》。头孢地尼颗粒属第三代头孢类抗生素，主要是通过抑制细菌细胞壁的合成而起到杀菌作用，是一种广谱的抗菌素，于2002年在中国获批上市。适用于治疗对头孢地尼敏感的葡萄球菌属、链球菌属、肺炎球菌、消化链球菌、丙酸杆菌、淋病奈瑟氏菌、卡他莫拉菌、大肠埃希菌、克雷伯菌属、奇异变形杆菌、普鲁威登斯菌属、流感嗜血杆菌等菌株所引起的感染，是一种同时适用于成人与儿童的抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0188","BK1197","BK0070","BK1521","00874","600332","BK0028","BK0175","BK1606","BK1515","BK0012","BK0096","BK0097","BK0196","BK0183","BK0239"],"gpt_icon":0},{"id":"2485249804","title":"白云山：子公司复方感冒灵胶囊获得《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2485249804","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485249804?lang=zh_cn&edition=full","pubTime":"2024-11-21 20:35","pubTimestamp":1732192537,"startTime":"0","endTime":"0","summary":"证券日报网讯11月21日晚间，白云山发布公告称，近日，公司子公司广州白云山中一药业有限公司收到国家药品监督管理局签发的《药品补充申请批准通知书》，药品通用名称为复方感冒灵胶囊。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411213246959970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1521","BK1606","BK1191","BK1515","BK1197","00874"],"gpt_icon":0},{"id":"2485465687","title":"白云山(00874)子公司获得药品补充申请批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2485465687","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485465687?lang=zh_cn&edition=full","pubTime":"2024-11-21 18:39","pubTimestamp":1732185562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山 发布公告，该公司子公司广州白云山中一药业有限公司收到国家药品监督管理局签发的《药品补充申请批准通知书》。中一药业于2024年10月22日向国家药监局递交本药品补充申请，于2024年10月25日获得受理。中一药业本次获得复方感冒灵胶囊《药品补充申请批准通知书》，有利于本公司优化资源配置，继续保持稳定的生产能力，满足市场需求。本次获得《药品补充申请批准通知书》，对本公司当期业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0097","BK1515","BK0096","BK1521","BK1606","BK0239","BK0183","BK1197","600332","BK0012","BK0175","BK0028","BK0188","00874","BK0070","BK1191"],"gpt_icon":0},{"id":"2485655944","title":"白云山最新公告：子公司中一药业获得复方感冒灵胶囊药品补充申请批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2485655944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485655944?lang=zh_cn&edition=full","pubTime":"2024-11-21 18:31","pubTimestamp":1732185097,"startTime":"0","endTime":"0","summary":"白云山公告，子公司中一药业收到国家药监局签发的《药品补充申请批准通知书》，批准复方感冒灵胶囊的药品上市许可持有人由“广州白云山奇星药业有限公司”变更为“广州白云山中一药业有限公司”。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100030087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0097","BK1515","BK0096","BK1521","BK1606","BK0239","BK0183","BK1197","600332","BK0012","BK0175","BK0028","BK0188","00874","BK0070","BK1191"],"gpt_icon":0},{"id":"2484169628","title":"白云山(00874.HK)分公司何济公药厂新增生产线和生产范围获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2484169628","media":"阿斯达克财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484169628?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:42","pubTimestamp":1732092120,"startTime":"0","endTime":"0","summary":"白云山(00874.HK) (600332.SH) 公布，其分公司何济公药厂近日收到广东省药品监督管理局核准签发的《药品生产许可证》，同意何济公药厂新增生产线和生产范围，并通过药品生产质量管理规范检查。(jl/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-20 16:25。) (A股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200312162542031_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200312162542031_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1398220/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1197","BK1521","BK0012","BK0097","BK0183","BK1606","BK1191","BK0070","BK0196","BK0239","BK0175","BK0028","BK0188","BK1515","BK0096","00874","600332"],"gpt_icon":0},{"id":"2484660351","title":"白云山(00874)：何济公药厂《药品生产许可证》变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2484660351","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484660351?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:39","pubTimestamp":1732091948,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，近日，广州白云山医药集团股份有限公司(以下简称“本公司”)分公司广州白云山医药集团股份有限公司白云山何济公制药厂(以下简称“何济公药厂”)收到广东省药品监督管理局核准签发的《药品生产许可证》，同意何济公药厂新增生产线和生产范围，并通过药品生产质量管理规范检查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","BK0175","BK1515","BK1606","BK0097","BK0012","BK0196","BK0028","BK0188","BK0070","BK0239","BK1197","BK1191","00874","BK0096","600332","BK0183"],"gpt_icon":0},{"id":"2484006165","title":"白云山(600332.SH)分公司何济公药厂新增生产线和生产范围获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2484006165","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484006165?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:23","pubTimestamp":1732091039,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(600332.SH)发布公告，公司分公司广州白云山医药集团股份有限公司白云山何济公制药厂(简称“何济公药厂”)收到广东省药品监督管理局核准签发的《药品生产许可证》，同意何济公药厂新增生产线和生产范围，并通过药品生产质量管理规范检查。同意何济公药厂在生产地址“广州市荔湾路49号”生产车间“荔湾制造部”新增生产线“喷雾剂生产线”、新增生产范围“喷雾剂”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0097","BK1191","BK0070","BK1521","BK0175","BK0183","BK1197","00874","600332","BK1606","BK0196","BK0028","BK1515","BK0188","BK0239","BK0096"],"gpt_icon":0},{"id":"2484547279","title":"净利润持续下滑，白云山面临业绩与合规双重压力","url":"https://stock-news.laohu8.com/highlight/detail?id=2484547279","media":"中访网财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484547279?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:38","pubTimestamp":1731983885,"startTime":"0","endTime":"0","summary":"近日，白云山发布了2024年三季度报告。财报显示，公司2024年前三季度实现营业收入590.6亿元，同比增长1.50%，实现归属净利润31.59亿元，同比下滑16.68%。      据了解，白云山....","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OwBpI1AjagaaVhyabIb06cd_Mf0qtuurUi7tNT-pijgjoAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OwBpI1AjagaaVhyabIb06cd_Mf0qtuurUi7tNT-pijgjoAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241119A02UV500","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241119A02UV500","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["00874"],"gpt_icon":0},{"id":"2484964020","title":"白云山(00874)附属明兴药业收到广东省药品监督管理局核准签发的《药品生产许可证》","url":"https://stock-news.laohu8.com/highlight/detail?id=2484964020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484964020?lang=zh_cn&edition=full","pubTime":"2024-11-18 19:05","pubTimestamp":1731927941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，近日，该公司全资子公司广州白云山明兴制药有限公司(以下简称“明兴药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》，同意明兴药业新增生产车间、生产线和生产范围，并通过药品生产质量管理规范符合性检查。本次明兴药业新增生产车间、生产线和生产范围，并通过药品生产质量管理规范符合性检查，有利于其优化产能，提升智能化、数字化、绿色化水平，继续保持稳定的生产能力，满足市场需求。本次获得《药品生产许可证》，对公司当期业绩无重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0097","BK1191","BK0070","BK1521","BK0175","BK0183","BK1197","00874","600332","BK1606","BK0196","BK0028","BK1515","BK0188","BK0239","BK0096"],"gpt_icon":0},{"id":"2484628848","title":"白云山子公司《药品生产许可证》变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2484628848","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484628848?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:51","pubTimestamp":1731927084,"startTime":"0","endTime":"0","summary":"格隆汇11月18日丨白云山公告，近日，广州白云山医药集团股份有限公司全资子公司广州白云山明兴制药有限公司收到广东省药品监督管理局核准签发的《药品生产许可证》，同意明兴药业新增生产车间、生产线和生产范围，并通过药品生产质量管理规范符合性检查。本次获得《药品生产许可证》，对本公司当期业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118185125abcc4df1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118185125abcc4df1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1197","BK1515","BK1521","BK1191","00874","BK1606"],"gpt_icon":0},{"id":"2484748316","title":"白云山，“千亿市值”梦难圆","url":"https://stock-news.laohu8.com/highlight/detail?id=2484748316","media":"经理人杂志","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484748316?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:30","pubTimestamp":1731922200,"startTime":"0","endTime":"0","summary":"以下文章来源于于见专栏，作者虞尔湖","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OF4NYhXzmk1rE8LZQzTX1vYqrRE5BYqjxzpxrfawreWN8AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OF4NYhXzmk1rE8LZQzTX1vYqrRE5BYqjxzpxrfawreWN8AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241118A077YB00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241118A077YB00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["00874","BK1521","BK1606","BK1515","BK1197","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gybys.com.cn","stockEarnings":[{"period":"1week","weight":-0.0066},{"period":"1month","weight":-0.0577},{"period":"3month","weight":-0.0419},{"period":"6month","weight":-0.1561},{"period":"1year","weight":-0.1409},{"period":"ytd","weight":-0.1212}],"compareEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":-0.0695},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.051},{"period":"1year","weight":0.0932},{"period":"ytd","weight":0.1239}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广州白云山医药集团股份有限公司从事制药和保健行业。该公司的业务分部包括：大南药分部、大健康分部、大商业分部和大医疗分部。大南药分部从事研究、开发、制造和销售中西成药、化学原料药、天然药物、生物医药和化学原料药中间体业务。大健康分部从事研究、开发、制造和销售饮料、食品、保健品等产品。大商业分部从事批发、零售和进出口西药、中药和医疗器械业务。大医疗分部从事医疗服务、中医养生、现代养老以及医疗器械产业。","yearOnYearQuotes":[{"month":1,"riseRate":0.423077,"avgChangeRate":-0.011967},{"month":2,"riseRate":0.692308,"avgChangeRate":0.062033},{"month":3,"riseRate":0.62963,"avgChangeRate":0.059521},{"month":4,"riseRate":0.666667,"avgChangeRate":0.087941},{"month":5,"riseRate":0.555556,"avgChangeRate":0.049452},{"month":6,"riseRate":0.481481,"avgChangeRate":0.021437},{"month":7,"riseRate":0.407407,"avgChangeRate":-0.018239},{"month":8,"riseRate":0.37037,"avgChangeRate":-0.039061},{"month":9,"riseRate":0.407407,"avgChangeRate":-0.011257},{"month":10,"riseRate":0.407407,"avgChangeRate":0.002825},{"month":11,"riseRate":0.428571,"avgChangeRate":0.008391},{"month":12,"riseRate":0.538462,"avgChangeRate":0.027564}],"exchange":"SEHK","name":"白云山","nameEN":"BAIYUNSHAN PH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"白云山(00874)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供白云山(00874)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"白云山,00874,白云山股票,白云山股票老虎,白云山股票老虎国际,白云山行情,白云山股票行情,白云山股价,白云山股市,白云山股票价格,白云山股票交易,白云山股票购买,白云山股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"白云山(00874)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供白云山(00874)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}